Sustiva
Efavirenz tablets for HIV-1 infection. They stop the virus from replicating by blocking its reverse transcriptase enzyme.
All strengths and pack prices
| Strength | Pack | Price | Per unit |
|---|---|---|---|
| 200mg | 10 tablets | $88.00 | $8.80 |
| 200mg | 20 tablets | $165.00 | $8.25 |
| 200mg | 30 tablets | $236.00 | $7.87 |
| 200mg | 60 tablets | $417.00 | $6.95 |
| 200mg | 90 tablets | $578.00 | $6.42 |
| 200mg | 120 tablets | $726.00 | $6.05 |
| 200mg | 180 tablets | $1022.00 | $5.68 |
| 200mg | 270 tablets | $1484.00 | $5.50 |
| 200mg | 360 tablets | $1913.00 | $5.31 |
| 600mg | 10 tablets | $106.00 | $10.60 |
| 600mg | 20 tablets | $206.00 | $10.30 |
| 600mg | 30 tablets | $290.00 | $9.67 |
| 600mg | 60 tablets | $526.00 | $8.77 |
| 600mg | 90 tablets | $745.00 | $8.28 |
| 600mg | 120 tablets | $937.00 | $7.81 |
| 600mg | 180 tablets | $1320.00 | $7.33 |
| 600mg | 270 tablets | $1851.00 | $6.86 |
| 600mg | 360 tablets | $2297.00 | $6.38 |
- Category
- HIV Management
- Active ingredient
- Efavirenz
- Route
- Oral use
- Form
- Tablet
- Strengths
- 200mg · 600mg
Sustiva is the reference name. You receive a generic with the same active ingredient and strength.
No prescription needed: we place your order for Sustiva on your behalf.
Sustiva details
- Alternative names
- efavirenz
- Therapeutic class
- Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
- Pharmacological class
- NNRTI
- Contraindications
- concurrent use of highly CYP3A4-dependent medications; severe hepatic impairment
- Minor side effects
- dizziness; headache; insomnia
- Moderate side effects
- vivid dreams; rash; fatigue
- Dosage forms
- Tablet
- Administration route
- Oral use
- Originator
- Bristol-Myers Squibb
- Onset time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Rifampin; Simvastatin; St. John's Wort
- Age restrictions
- Approved for children over three months and adults.
Serious side effects
severe depression and suicidal ideation, requires immediate medical attention; severe hepatotoxicity, requires immediate medical attention
Patient summary
Efavirenz tablets for HIV-1 infection. They stop the virus from replicating by blocking its reverse transcriptase enzyme.
Mechanism of action
Non-competitively inhibits HIV-1 reverse transcriptase, halting viral replication inside host cells.
Pregnancy and breastfeeding
Pregnancy: Potential risk of neural tube defects. Avoid in first trimester. Breastfeeding: Not recommended.
What you will receive
Sustiva names the medicine you are looking for. What ships is a generic version of it.
- A generic containing Efavirenz at the strength you pick.
- Which generic brand and maker ships depends on stock and destination.
- Check the active ingredient, strength, form, pack, seal, batch and expiry when it arrives.